Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juvista for Scar Improvement in Healthy Males
NCT00594581Phase 2Completed
- Sponsor
- Renovo
- Start
- Oct 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avotermin in cicatrix (2 arms), sponsored by Renovo. Primary endpoint: Scar appearance at 12 months. Started Oct 2003; status: completed.
02
Drugs
avotermin
03
Conditions
cicatrix
Beyond the preview
Go deeper on NCT00594581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594581.